Dovitinib targets FGFR1/2/3 and is under clinical trial investigation as an anti-tumor drug, with FGFR1 chromosomal translocation associated with 8p11 myeloproliferative syndrome, and FGFR3 is implicated in multiple myeloma and peripheral T-cell lymphoma [105]. This evidence concerns the gene FGFR3 and plasma cell myeloma.